

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **MedSci Healthcare Holdings Limited**

### **梅斯健康控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2415)**

## **CHANGE IN CO-CHIEF EXECUTIVE OFFICER AND APPOINTMENT OF CHIEF OPERATING OFFICER**

The board (the “**Board**”) of directors (the “**Director(s)**”) of MedSci Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from 16 July 2024:

- (i) Mr. Fan Jie (樊傑) (“**Mr. Fan**”), an executive Director and the co-chief executive officer of the Group, has ceased to be co-chief executive officer of the Group;
- (ii) Mr. Wang Shuai (王帥) (“**Mr. Wang**”), an executive Director, has been appointed as the co-chief executive officer of the Group; and
- (iii) Mr. Cheng Liang (程亮) (“**Mr. Cheng**”) has been appointed as the chief operating officer of the Group.

### **Cessation as co-chief executive officer**

Due to work reassignment to the Innovation Department (創新事務部) of the Group, Mr. Fan Jie has ceased to be co-chief executive officer of the Group, but he would remain as executive Director. Mr. Fan confirmed that he has no disagreement with the Board and there are no matters relating to his cessation as the co-chief executive officer of the Group that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

## **Appointment of co-chief executive officer**

The biographical details of Mr. Wang are set out below:

Mr. Wang, aged 43, was appointed as a Director in November 2021, and re-designated as an executive Director in April 2022. Mr. Wang has also been the Group's vice president since December 2021. He is responsible for the overall strategic planning and general management and execution of the business operations of the Group. Mr. Wang has also been serving as a vice president and director of Shanghai MedSci MedTech Co., Ltd. since June 2016 and September 2020, respectively. Mr. Wang obtained a bachelor's degree in clinical medicine from China Medical University (中國醫科大學) in the PRC in July 2003.

Prior to joining the Group, Mr. Wang worked at Beijing Xunbo Hengtai Technology Development Co., Ltd. (北京訊博恒泰科技發展有限公司), a company primarily engaged in medical advertisement, from November 2007 to August 2011, mainly responsible for providing medical consulting services to pharmaceutical companies. Subsequently, Mr. Wang worked at Beijing KINGYEE Technology Co., Ltd. (北京金葉天盛科技有限公司), an internet physician platform company primarily engaged in providing digital marketing solutions for pharmaceutical companies from December 2011 to October 2013, and served as the sales director of KINGYEE (Beijing) Co., Ltd. (金葉天成(北京)科技有限公司) from November 2013 to December 2015, responsible for the sales and sales management. Mr. Wang also served as the general manager at Beijing Chaokanglian Information Technology Co., Ltd. (北京朝康聯信息科技有限公司), a company primarily engaged in medical advertisement, from January 2016 to June 2016, responsible for operation management.

Pursuant to the service contract entered into between the Company and Mr. Wang, Mr. Wang is not entitled to director's fee.

Save as disclosed above, as at the date of this announcement, Mr. Wang does not (1) have any relationships with any directors, senior management or substantial or controlling shareholders of the Company, (2) have any interests in shares of the Company and associated corporation of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)), (3) hold any directorships in listed public companies in the last three years, and (4) have any other information that needs to be disclosed pursuant to any of the requirements as set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

## **Appointment of chief operating officer**

The biographical details of Mr. Cheng are set out below:

Mr. Cheng, aged 42, joined the Group in June 2020 and is currently responsible for legal compliance and strategic cooperation of the Group. Mr. Cheng has 11 years of experience in the consulting industry and 5 years of experience in information technology companies. Prior to joining the Group, Mr. Cheng successively served as a customer manager at Uniland Consulting (Shanghai) Co., Ltd. (優利諮詢(上海)有限公司), a senior consulting manager at Livingston Market Consultants (上海歐逸市場行銷顧問有限公司), a key customer manager at Dabang (Shanghai) Management Co., Ltd.\* (達邦(上海)管理有限公司), and a director at Haier Asia International (海爾亞洲國際株式會社). Mr. Cheng is currently a member of the International Management Consulting Association and a National Certified Management Consultant in China. Mr. Cheng received a bachelor's degree in management and a master's degree in business administration for senior management from Shanghai Jiao Tong University (上海交通大學) in 2004 and 2017, respectively.

The Board would like to congratulate Mr. Cheng on his new role as the chief operating officer of the Group.

By order of the Board  
**MedSci Healthcare Holdings Limited**  
**梅斯健康控股有限公司**  
**Dr. Zhang Fabao**

*Chairman of the Board and Executive Director*

Hong Kong, 16 July 2024

*As at the date of this announcement, the Board of Directors comprises Dr. Zhang Fabao, Dr. Li Xinmei, Mr. Fan Jie and Mr. Wang Shuai, as executive Directors; Mr. Hu Xubo and Mr. Yan Shengfeng, as non-executive Directors; and Ms. Liu Tao, Mr. Yu Mingyang and Mr. Lau Yiu Kwan Stanley, as independent non-executive Directors.*